ArticleInternational journal of molecular sciences2024
Naphthoquinone-Quinolone Hybrids with Antitumor Effects on Breast Cancer Cell Lines-From the Synthesis to 3D-Cell Culture Effects.
Vanessa da Gama Oliveira, Marcelly Muxfeldt, Mariana Muniz da Paz, Mayra Silva Coutinho, Raissa Eduardo Dos Santos, Giulia Diniz da Silva Ferretti, Danielly C Ferraz da Costa, Pedro Fonseca Regufe, Ivson Lelis Gama, Fernanda da Costa Santos Boechat and 6 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Vanessa da Gama OliveiraInstituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0002-5333-9038 Marcelly MuxfeldtFaculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Mariana Muniz da PazFaculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Mayra Silva CoutinhoInstituto de Química, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.ORCID 0009-0003-4968-2604 Raissa Eduardo Dos SantosFaculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Giulia Diniz da Silva FerrettiInstituto de Bioquimica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Danielly C Ferraz da CostaInstituto de Nutrição, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, RJ, Brazil.
Pedro Fonseca RegufeInstituto de Química, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.
Ivson Lelis GamaInstituto de Química, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.
Fernanda da Costa Santos BoechatInstituto de Química, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.
Emersom Silva LimaFaculdade de Ciências Farmacêuticas, Universidade Federal do Amazonas, Manaus 69067-005, AM, Brazil.ORCID 0000-0002-9367-2812 Vitor Francisco FerreiraFaculdade de Farmácia, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.ORCID 0000-0002-2166-766X Marcela Cristina de MoraesInstituto de Química, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.ORCID 0000-0001-7448-5301 Maria Cecília Bastos Vieira de SouzaInstituto de Química, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.ORCID 0000-0003-0318-3087 Pedro Netto BatalhaInstituto de Química, Universidade Federal Fluminense, Niteroi 24020-141, RJ, Brazil.ORCID 0000-0002-8426-6898 Luciana Pereira RangelFaculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0002-6154-0815 Funding
Lacrimal Gland Repair Using Progenitor CellsR01EY026202 · NEI · SCRIPPS RESEARCH INSTITUTE, THE · PI MAKARENKOVA, HELEN P. · 2016 to 2025
$5.2MCoordenação de Aperfeicoamento de Pessoal de Nível Superior 001Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/010.002128/2019Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/010.101106/2018Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/201.057/2021(260306)Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/201.324/2021Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/201.416/2022Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/202.361/2017Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/203.044/2016Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/203.298/2017Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/211.337/2021Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro SEI-260003/001131/2020National Council for Scientific and Technological Development 312864/2018-3National Council for Scientific and Technological Development 314933/2020-4National Council for Scientific and Technological Development 465395/2014-7
6 · The paper itselfAbstract
Breast cancer stands as one of the foremost cause of cancer-related deaths globally, characterized by its varied molecular subtypes. Each subtype requires a distinct therapeutic strategy. Although advancements in treatment have enhanced patient outcomes, significant hurdles remain, including treatment toxicity and restricted effectiveness. Here, we explore the anticancer potential of novel 1,4-naphthoquinone/4-quinolone hybrids on breast cancer cell lines. The synthesized compounds demonstrated selective cytotoxicity against Luminal and triple-negative breast cancer (TNBC) cells, which represent the two main molecular types of breast cancer that depend most on cytotoxic chemotherapy, with potency comparable to doxorubicin, a standard chemotherapeutic widely used in breast cancer treatment. Notably, these derivatives exhibited superior selectivity indices (SI) when compared to doxorubicin, indicating lower toxicity towards non-tumor MCF10A cells. Compounds 11a and 11b displayed an improvement in IC
Indexed as
Antineoplastic AgentsBreast NeoplasmsNaphthoquinonesApoptosisCell Culture Techniques, Three DimensionalCell Line, TumorCell ProliferationCell SurvivalDoxorubicinFemaleHumansMCF-7 CellsQuinolonesAntineoplastic AgentsDoxorubicinNaphthoquinonesQuinolones1,4-naphthoquinone4-quinoloneanticancerbreast cancer
Identifiers
PMID38928197
PMCPMC11203957
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390